Graham Casey
Department of Cancer Biology
ND50, Lerner Research Institute
Cleveland Clinic Foundation
USA
Name/email consistency: high
- Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. Casey, G., Neville, P.J., Liu, X., Plummer, S.J., Cicek, M.S., Krumroy, L.M., Curran, A.P., McGreevy, M.R., Catalona, W.J., Klein, E.A., Witte, J.S. Hum. Mol. Genet. (2006)
- Conversion analysis for mutation detection in MLH1 and MSH2 in patients with colorectal cancer. Casey, G., Lindor, N.M., Papadopoulos, N., Thibodeau, S.N., Moskow, J., Steelman, S., Buzin, C.H., Sommer, S.S., Collins, C.E., Butz, M., Aronson, M., Gallinger, S., Barker, M.A., Young, J.P., Jass, J.R., Hopper, J.L., Diep, A., Bapat, B., Salem, M., Seminara, D., Haile, R. JAMA (2005)
- RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Casey, G., Neville, P.J., Plummer, S.J., Xiang, Y., Krumroy, L.M., Klein, E.A., Catalona, W.J., Nupponen, N., Carpten, J.D., Trent, J.M., Silverman, R.H., Witte, J.S. Nat. Genet. (2002)